Swiss drugmaker Roche and the Cambodia Treatment Access Program (CTAP) have enrolled more than 1,000 men, women and children infected with HIV/AIDS to receive care and treatment free-of-charge in the country. The aim of the collaboration, which was first established in 2003 as a three-way partnership between the Cambodian Ministry of Health, the National Center in HIV Epidemiology and Clinical Research in Australia and Roche, is to help tackle HIV/AIDS in Cambodia -- which has the highest disease-prevalence rate in Asia.
"The achievement of CTAP demonstrates what can be achieved through collaboration," said William Burns, CEO of Roche's pharmaceuticals division. "To tackle diseases such as HIV/AIDS, it is vital that we use our skills and resources, together with those of other expert organizations. With global funding now reaching Cambodia, we expect to provide treatment to increasing numbers of people at the CTAP social health clinic."